Journal of Cancer Therapy

Volume 4, Issue 3 (March 2013)

ISSN Print: 2151-1934   ISSN Online: 2151-1942

Google-based Impact Factor: 0.52  Citations  h5-index & Ranking

Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy

HTML  Download Download as PDF (Size: 194KB)  PP. 448-451  
DOI: 10.4236/jct.2013.43A054    3,681 Downloads   6,230 Views  

ABSTRACT

The prognosis of CD20-positive (CD20+) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) recurrence is still poor. A standard treatment for CD20+ DLBCL with CNS recurrence in elderly patients has not been established mainly due to adverse effects. We previously reported the efficacy and safety of MIND-E (ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide) therapy for elderly CD20+ DLBCL patients with CNS recurrence. Here, we report the use of R-MIND-E therapy (rituximab, ranimustine, ifosfamide, procarbazine, dexamethasone and etoposide) in an elderly CD20+ DLBCL patient with CNS recurrence. The patient achieved a complete response according to Revised Response Criteria for Malignant Lymphoma, and treatment-related toxicity was tolerable. R-MIND-E therapy may be a feasible and useful treatment option for elderly CD20+ DLBCL patients with CNS recurrence.

Cite this paper

J. Miyahara, N. Takezako, M. Wagatsuma, K. Midorikawa, I. Fukuda, S. Noto, I. Saito, K. Yamada, A. Miwa and N. Sekiguchi, "Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy," Journal of Cancer Therapy, Vol. 4 No. 3A, 2013, pp. 448-451. doi: 10.4236/jct.2013.43A054.

Cited by

No relevant information.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.